Oritavancin
CAS: 171099-57-3
Ref. 3D-AA16180
2mg | 274,00 € | ||
5mg | 469,00 € | ||
10mg | 715,00 € | ||
25mg | 1.298,00 € | ||
50mg | 1.953,00 € |
Informação sobre produto
- (4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin
- (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin
- Ly-333328
- Orbactiv
- Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-<span class="text-smallcaps">L</span>-arabino-hexopyranosyl)-N<sup>3′′</sup>-[(4′-chloro[1,1′-biphenyl]-4-yl)methyl]-, (4′′R)-
- Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3′′-[(4′-chloro[1,1′-biphenyl]-4-yl)methyl]-, (4′′R)-
Oritavancin is a semi-synthetic lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine moiety of peptidoglycan precursors. It has been shown to be active against methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium perfringens. Oritavancin also inhibits the growth of thp-1 cells in vitro and has been shown to be effective against endocarditis caused by MRSA.
Propriedades químicas
Consulta técnica sobre: 3D-AA16180 Oritavancin
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.